Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.51 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 4/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888559 | 0.90 | USP2 (0.62) | USP2PLA2G2CHTTLPAR1LPAR3 | |
| SCHEMBL19257795 | 0.90 | USP2 (0.61) | USP2PLA2G2CHTTLPAR1LPAR3 | |
| SCHEMBL702717 | 0.89 | USP2 (0.65) | USP2PLA2G2CHTTLPAR1LPAR3 | |
| SCHEMBL19257791 | 0.88 | USP2 (0.58) | USP2HTTLPAR1LPAR3LPAR2 | |
| SCHEMBL19257788 | 0.88 | USP2 (0.53) | USP2PLA2G2CLPAR1LPAR3LPAR2 | |
| SCHEMBL19257790 | 0.86 | USP2 (0.82) | USP2PLA2G2CHTTLPAR1LPAR3 | |
| SCHEMBL19257789 | 0.86 | USP2 (0.82) | USP2PLA2G2CHTTLPAR1LPAR3 | |
| SCHEMBL21122157 | 0.86 | USP2 (0.82) | USP2PLA2G2CHTTLPAR1LPAR3 | |
| SCHEMBL19257792 | 0.86 | LPAR1 (0.59) | USP2PLA2G2CHTTLPAR1LPAR3 | |
| SCHEMBL10420319 | 0.85 | USP2 (0.80) | USP2PLA2G2CHTTLPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233337-A1 | NON-IONIC AMPHIPHILES AND METHODS OF MAKING THE SAME | ARCHER DANIELS MIDLAND CO (IL) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233337-A1 | NON-IONIC AMPHIPHILES AND METHODS OF MAKING THE SAME | PNLIP, FFAR4, SPTLC2 | USP2 2124/4885PLA2G2C 149/4885HTT 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.